NEW YORK (GenomeWeb) – Illumina today announced that its startup accelerator has secured $40 million from Viking Global Investors to fund promising genomic firms.

Accelerator graduates that raise between $1 million and $5 million in new capital will receive additional dollar-for-dollar match funding from Illumina Accelerator Boost Capital.

"This capital commitment will be instrumental in driving value for our startups as they advance breakthrough applications in genomics," Amanda Cashin, head of Illumina Accelerator, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.